Rev Esp Patol 2022 Jul-Sep;55(3):156-162. Epub 2022 Apr 25.
BIOPAT, Biopatologia Molecular SL, Grup Assistència, Avenida Diagonal, 660, 08034, Barcelona, Spain; Histopat Laboratoris SL, Calle Mendel, 1, 08034, Barcelona, Spain; SCIAS-Hospital de Barcelona, Grup Assistència, Avenida Diagonal, 660, 08034, Bracelona, Spain.
Introduction: Analysis of circulating tumor DNA (ctDNA), also known as liquid biopsy, has been postulated to be a useful test in the prognostication, molecular profiling, and monitoring of cancer patients. In this series we aimed to analyze the concordance between the mutation status of formalin-fixed paraffin-embedded (FFPE) tumor samples and matched ctDNA, considering tumor molecular profiling as the gold standard technique.
Methods: This retrospective study included cancer patients with complete diagnostics and gene mutations detected in a previous FFPE tumor tissue Next-Generation Sequencing (NGS) study with a matched frozen plasma sample available for an NGS ctDNA assay. Read More